Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Mar;48(3):1004-6.
doi: 10.1128/AAC.48.3.1004-1006.2004.

Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models

Affiliations

Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models

E Dadachova et al. Antimicrob Agents Chemother. 2004 Mar.

Abstract

We evaluated acute hematological and long-term pulmonary toxicity of radioimmunotherapy in murine models of Cryptococcus neoformans infection. Activities up to 250 microCi were well tolerated by healthy A/JCr mice for (213)Bi-18B7 and (188)Re-18B7 monoclonal antibodies. In infected mice, doses up to 150 microCi produced only transient toxicity. The lungs of treated mice had no evidence of radiation fibrosis.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Platelet counts in A/JCr mice. Healthy mice (a and c) and C. neoformans-infected mice (b and d) received various doses of 213Bi-18B7 (a and b) or 188Re-18B7 (c and d). A “0” indicates infected nontreated mice. C. neoformans-infected mice treated with 200 and 250 μCi of 213Bi-18B7 (b) died by day 7 posttreatment. The platelet count in healthy nontreated A/JCr mice was (8.8 ± 2.4) × 108 platelets/ml.
FIG. 2.
FIG. 2.
Micrographs of hematoxylin-and-eosin-stained lungs from BALB/c mice infected IT with C. neoformans and treated with radiolabeled antibodies. Mice were sacrificed 5 months after RIT. (a) Infected control for Bi group (no RIT); (b) 200 μCi of 213Bi-18B7; (c) infected control for Re group (no RIT); (c) 200 μCi of 188Re-18B7.

References

    1. Behr, T. M., M. Behe, M. G. Stabin, E. Wehrmann, C. Apostolidis, R. Molinet, F. Strutz, A. Fayyazi, E. Wieland, S. Gratz, L. Koch, D. M. Goldenberg, and W. Becker. 1999. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res. 59:2635-2643. - PubMed
    1. Dadachova, E., R. W. Howell, R. A. Bryan, A. Frenkel, J. D. Nosanchuk, and A. Casadevall. Susceptibility of human pathogens Cryptococcus neoformans and Histoplasma capsulatum to gamma radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J. Nucl. Med., in press. - PubMed
    1. Dadachova, E., A. Nakouzi, R. A. Bryan, and A. Casadevall. 2003. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc. Natl. Acad. Sci. USA 100:10942-10947. - PMC - PubMed
    1. Knox, S. J., and R. F. Meredith. 2000. Clinical radioimmunotherapy. Semin. Radiat. Oncol. 10:73-93. - PubMed
    1. Koenig, T. R., R. F. Munden, J. J. Erasmus, B. S. Sabloff, G. W. Gladish, R. Komaki, and C. W. Stevens. 2002. Radiation injury of the lung after three-dimensional conformal radiation therapy. Am. J. Roentgenol. 178:1383-1388. - PubMed

Publication types